ID   U3013MG
AC   CVCL_IR61
SY   U3013-MG; U3013
DR   cancercelllines; CVCL_IR61
DR   ChEMBL-Cells; CHEMBL4483163
DR   GEO; GSM1857572
DR   GEO; GSM1857788
DR   Progenetix; CVCL_IR61
DR   PubChem_Cell_line; CVCL_IR61
DR   Wikidata; Q54973679
RX   PubMed=26629530;
RX   PubMed=27689322;
RX   PubMed=28122246;
WW   http://www.hgcc.se/
CC   Part of: Human Glioblastoma Cell Culture (HGCC) resource.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Derived from site: In situ; Brain; UBERON=UBERON_0000955.
ST   Source(s): PubMed=26629530
ST   Amelogenin: X
ST   CSF1PO: 10,12
ST   D13S317: 14
ST   D16S539: 10
ST   D18S51: 13,14
ST   D19S433: 14
ST   D21S11: 31.2,32.2
ST   D2S1338: 25,26
ST   D3S1358: 17,19
ST   D5S818: 12
ST   D7S820: 9,11
ST   D8S1179: 13,14
ST   FGA: 18,24
ST   TH01: 6,9.3
ST   TPOX: 8
ST   vWA: 16
DI   NCIt; C3058; Glioblastoma
DI   ORDO; Orphanet_360; Glioblastoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   78Y
CA   Cancer cell line
DT   Created: 03-03-17; Last updated: 05-10-23; Version: 9
//
RX   PubMed=26629530; DOI=10.1016/j.ebiom.2015.08.026;
RA   Xie Y., Bergstrom T., Jiang Y.-W., Johansson P., Marinescu V.D.,
RA   Lindberg N., Segerman A., Wicher G., Niklasson M., Baskaran S.,
RA   Sreedharan S., Everlien I., Kastemar M., Hermansson A., Elfineh L.,
RA   Libard S., Holland E.C., Hesselager G., Alafuzoff I., Westermark B.,
RA   Nelander S., Forsberg-Nilsson K., Uhrbom L.;
RT   "The Human Glioblastoma Cell Culture resource: validated cell models
RT   representing all molecular subtypes.";
RL   EBioMedicine 2:1351-1363(2015).
//
RX   PubMed=27689322; DOI=10.18632/oncotarget.12298;
RA   Schmidt L., Baskaran S., Johansson P., Padhan N., Matuszewski D.J.,
RA   Green L.C., Elfineh L., Wee S.-M., Haggblad M., Martens U.,
RA   Westermark B., Forsberg-Nilsson K., Uhrbom L., Claesson-Welsh L.,
RA   Andang M., Sintorn I.-M., Lundgren B., Lonnstedt I., Krona C.,
RA   Nelander S.;
RT   "Case-specific potentiation of glioblastoma drugs by pterostilbene.";
RL   Oncotarget 7:73200-73215(2016).
//
RX   PubMed=28122246; DOI=10.1016/j.celrep.2017.01.003;
RA   Jiang Y.-W., Marinescu V.D., Xie Y., Jarvius M., Maturi N.P.,
RA   Haglund C., Olofsson S., Lindberg N., Olofsson T., Leijonmarck C.,
RA   Hesselager G., Alafuzoff I., Fryknas M., Larsson R., Nelander S.,
RA   Uhrbom L.;
RT   "Glioblastoma cell malignancy and drug sensitivity are affected by the
RT   cell of origin.";
RL   Cell Rep. 18:977-990(2017).
//